Newer effective personalized therapies, including poly-ADP-ribose polymerase (PARP) inhibitors targeting BRCA1 or BRCA2 pathogenic mutations directly or via their pathways are increasingly available for ovarian and breast cancer patients who are carriers of such variants [11]. This evidence concerns the gene BRCA1 and breast carcinoma.